Creative Life Science Co (ROCO:7837) EBIT: NT$150 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7837 Creative Life Science Co Ltd ROCO:7837
28 GF Score
Price NT$74.50
! 3 Warning Signs
View Full Analysis

What is Creative Life Science Co EBIT?

Creative Life Science Co ROCO:7837 +0.68% 28 EBIT is NT$150 Mil as of Jun. 2026. GuruFocus rates ROCO:7837 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Creative Life Science Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2026 was NT$62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$150 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Creative Life Science Co's annualized ROC % for the quarter that ended in Jun. 2026 was 9.01%. Creative Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 21.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Creative Life Science Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 8.64%.

Creative Life Science Co  (ROCO:7837) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Creative Life Science Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=106.674 * ( 1 - 14.94% )/( (984.305 + 1029.165)/ 2 )
=90.7369044/1006.735
=9.01 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1439.135 - 224.935 - ( 299.924 - max(0, 421.623 - 651.518+299.924))
=984.305

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1439.741 - 215.561 - ( 284.391 - max(0, 427.44 - 622.455+284.391))
=1029.165

Note: The Operating Income data used here is two times the semi-annual (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Creative Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=124.902/( ( (581.219 + max(-42.086, 0)) + (600.867 + max(-56.731, 0)) )/ 2 )
=124.902/( ( 581.219 + 600.867 )/ 2 )
=124.902/591.043
=21.13 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(186.891 + 116.556 + 13.434) - (224.935 + 0 + 134.032)
=-42.086

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(186.423 + 101.299 + 21.502) - (215.561 + 0 + 150.394)
=-56.731

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Creative Life Science Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=150.054/1737.542
=8.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Life Science Co EBIT Related Terms

Creative Life Science Co EBIT Historical Data

* Premium members only.

The historical data trend for Creative Life Science Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Life Science Co EBIT Chart

Creative Life Science Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
0.00 186.46 94.27 124.39 140.96

Creative Life Science Co Semi-Annual Data
Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
EBIT Get a 7-Day Free Trial 52.40 71.99 53.35 87.60 62.45

ROCO:7837 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Creative Life Science Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Creative Life Science Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Life Science Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Creative Life Science Co's EV-to-EBIT falls into.


ROCO:7837
28GF Score
Creative Life Science Co Ltd ROCO:7837
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creative Life Science Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$150 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$150 Mil mean?
Creative Life Science Co (ROCO:7837) has a EBIT of NT$150 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Creative Life Science Co.
Is Creative Life Science Co's EBIT too high?
Creative Life Science Co's current EBIT is NT$150 Mil. Overall, Creative Life Science Co has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Creative Life Science Co's EBIT compare to VRTX and REGN?
Creative Life Science Co's EBIT of NT$150 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Creative Life Science Co. Creative Life Science Co's current EBIT is NT$150 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Life Science Co stock overvalued right now?
Creative Life Science Co (ROCO:7837) has a current EBIT of NT$150 Mil. The current EBIT is NT$150 Mil. Creative Life Science Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Creative Life Science Co (ROCO:7837), the current EBIT is NT$150 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Creative Life Science Co Business Description

Address Wuquan 3rd Road, No. 24, Wugu District, New Taipei City, TWN, 248021
Creative Life Science Co Ltd is engaged in providing products of microbiology, and it has prepared media products and diagnostic reagents. The main products of CMP (Creative Media Plate) are solid and liquid media, which can be used for clinical microbiology, basic microbial research, environmental monitoring, biosafety testing, and quality control. Its product line is Transport Medium, Prepared Tube Media, Prepared Plated Media, VTM & I-VTM, Bacterial strain preservation system, and CMP SteriPack triple wrapped media.
28GF Score

Get the complete analysis for ROCO:7837

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.50
Price